25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 25 of 25 clinical reviews.
Does Tresiba protect the kidneys or put them at risk? A physician-reviewed deep dive into insulin degludec's renal profile, DEVOTE trial data, dosing in CKD, and practical clinical guidance.
A clinician-level review of insulin degludec (Tresiba) and cognitive function impact, covering hypoglycemia-driven brain injury, DEVOTE trial data, and practical dosing strategies to protect cognition in diabetes care.
Does Tresiba (insulin degludec) affect appetite and food cravings? A physician-reviewed deep-dive into the clinical evidence, mechanisms, and what patients can realistically expect.
Board-reviewed clinical guide covering insulin degludec (Tresiba) use in patients with autoimmune conditions, including type 1 diabetes, thyroid disease, celiac disease, and immune-mediated hypoglycemia. Covers DEVOTE trial data, dosing, and monitoring protocols.
A thorough clinical review of insulin degludec (Tresiba) and its effects on bone mineral density, fracture risk, and skeletal health, with primary-literature citations and dosing guidance for clinicians and patients.
A clinician-level review of the cancer risk signal associated with insulin degludec (Tresiba), covering IGF-1 receptor affinity data, DEVOTE trial findings, post-marketing surveillance, and current prescribing guidance.
A clinician-level review of insulin degludec (Tresiba) cardiovascular outcomes, covering DEVOTE trial data, hypoglycemia-driven cardiac risk, real-world registry findings, and how degludec compares to insulin glargine U-300 for long-term heart safety.
A physician-reviewed comparison of compounded insulin degludec vs branded Tresiba, covering pharmacokinetics, safety data, regulatory status, and how to choose between them.
A physician-level GRADE analysis of insulin degludec (Tresiba) covering DEVOTE, BEGIN, and SWITCH trials, hypoglycemia risk reduction, cardiovascular safety, and ADA/AACE guideline recommendations.
A physician-reviewed guide to insulin degludec (Tresiba) and its reported hair and skin effects, covering lipodystrophy, injection-site reactions, alopecia reports, and clinical management strategies with primary-literature citations.
A physician-level review of how insulin degludec (Tresiba) affects liver function, hepatic glucose output, and transaminase levels. Covers DEVOTE, pharmacokinetics, NAFLD, and dosing in hepatic impairment.
A physician-reviewed deep dive into how insulin degludec (Tresiba) affects mental health and mood, covering hypoglycemia-driven anxiety, diabetes distress, depression prevalence, and clinical management strategies.
A clinician-level review of how insulin degludec (Tresiba) affects metabolism, thermogenesis, and energy expenditure, covering pharmacokinetics, adipose tissue biology, clinical trial data, and practical prescribing implications.
A physician-level review of insulin degludec (Tresiba) microdosing protocols, covering pharmacokinetics, clinical trial data, dose-titration evidence, and practical guidance for type 1 and type 2 diabetes.
How to use Tresiba (insulin degludec) to minimize muscle catabolism in type 1 and type 2 diabetes. Evidence-based dosing, timing, and adjunct strategies reviewed by the HealthRX medical team.
Why your Tresiba (insulin degludec) dose has stopped working, and exactly what to do about it. MD-level guidance on diagnosing fasting hyperglycemia plateaus, dose-titration errors, timing problems, and when to switch basal insulin.
A comprehensive clinical review of insulin degludec (Tresiba) use after bariatric surgery, covering dose adjustment, hypoglycemia risk, pharmacokinetics, and transition strategies for type 1 and type 2 diabetes.
Exact guidance on when and how to hold or reduce Tresiba (insulin degludec) before surgery, with primary-literature citations, ADA/AACE recommendations, and a practical dosing framework for clinicians and patients.
A physician-reviewed guide to the physiological changes, rebound hyperglycemia risk, and safe tapering strategies when stopping Tresiba (insulin degludec), with primary-literature citations throughout.
Step-by-step guidance on restarting Tresiba (insulin degludec) safely after acute illness, with dose-adjustment protocols, monitoring timelines, and evidence from DEVOTE and ADA guidelines.
How temperature changes, activity shifts, and seasonal illness affect Tresiba (insulin degludec) dosing. Evidence-based guidance for clinicians and patients managing type 1 and type 2 diabetes year-round.
A clinician-level review of how insulin degludec (Tresiba) affects sexual function through glycemic control, hypoglycemia reduction, and indirect hormonal pathways. Includes DEVOTE trial data, primary literature citations, and a clinical decision framework.
A clinician-level review of how insulin degludec (Tresiba) affects sleep architecture, nocturnal hypoglycemia risk, and overnight glucose stability, with primary-literature citations and practical dosing guidance.
MD-level protocols for traveling with insulin degludec (Tresiba): timezone shifts, dose-timing flexibility, storage during transit, and hypoglycemia risk management. Backed by DEVOTE and ADA guidelines.
A week-by-week breakdown of what to expect in your first month on Tresiba (insulin degludec), backed by DEVOTE trial data, dosing guidance, and hypoglycemia risk timelines.